NCT01947868View on ClinicalTrials.gov

Evaluation of Symptoms Improvement in NSCLC Patients With First-Line Therapy of EGFR Tyrosine Kinase Inhibitor

CompletedOBSERVATIONAL
Enrollment

346

Participants

Timeline

Start Date

November 30, 2013

Primary Completion Date

September 30, 2015

Study Completion Date

September 30, 2015

Conditions
Non-Small-Cell Lung Cancer
Trial Locations (1)

Unknown

China Medical University Hospital, Taichung

Sponsors

Lead Sponsor

AstraZeneca
All Listed Sponsors
lead

AstraZeneca

INDUSTRY